MICHAEL SHEEHAN: Open Payments
NPI 1134388119 · COLUMBUS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$85,107 in 156 payments from 18 companies in 2025. Trend: 2023 $43,633 · 2024 $86,473 · 2025 $85,107
Speaker / faculty: $76,652Travel & lodging: $5,630Food & beverage: $2,825
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 33 | $40,976 |
| GENZYME CORPORATION | 18 | $25,917 |
| ABBVIE INC. | 37 | $16,804 |
| Galderma Laboratories, L.P. | 15 | $363 |
| PFIZER INC. | 9 | $219 |
| Janssen Biotech, Inc. | 10 | $163 |
| Amgen Inc. | 7 | $140 |
| LEO Pharma Inc. | 4 | $72 |
| UCB, Inc. | 3 | $69 |
| Novartis Pharmaceuticals Corporation | 4 | $64 |
Products named: DUPIXENT, RINVOQ, SKYRIZI, NEMLUVIO, TREMFYA, Otezla, LITFULO, CIBINQO.
Industry payments across IN — which companies pay providers there.
